Researchers from the University of Cambridge have created a new DNA sequencing method called Chem-map, which can detect where and how small molecule drugs interact with the targeted genome. The method enables researchers to conduct in situ mapping of small molecule-genome interactions with unprecedented precision. Chem-map was used in the study to determine the direct binding sites in human leukemia cells of the widely used anticancer drug doxorubicin. The study also showed how the combined therapy of doxorubicin and histone deacetylase (HDAC) inhibitor tucidinostat could have a potential clinical advantage. The technique could help develop better and safer drug therapies in the future.
Read More: Source: cam.ac.uk
